drugset / Trial / NCT06856187
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local treatment versus continuous treatment of standard second-line therapy in advanced colorectal cancer.
Timeline
- Start
- 2025-02-28
- Primary completion
- 2026-06-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | TAS-102 | Small molecule | — | — |
| Comparator | Cetuximab | Monoclonal antibody | — | — |